Lingfan Xu
Overview
Explore the profile of Lingfan Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
446
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen J, Wang F, Xu H, Xu L, Chen D, Wang J, et al.
Front Oncol
. 2024 Dec;
14:1501882.
PMID: 39655070
[This corrects the article DOI: 10.3389/fonc.2020.552907.].
2.
Gao D, Shen Y, Xu L, Sun Y, Hu H, Xu B, et al.
Drug Resist Updat
. 2024 Oct;
77:101158.
PMID: 39395327
Aims: Tumor fatty acid (FA) metabolic plasticity plays a pivotal role in resistance to therapy and poses limitations to anticancer strategies. In this study, our aim is to uncover the...
3.
Hauck J, Moon D, Jiang X, Wang M, Zhao Y, Xu L, et al.
Commun Biol
. 2024 Jan;
7(1):9.
PMID: 38172561
There are limited therapeutic options for patients with advanced prostate cancer (PCa). We previously found that heat shock factor 1 (HSF1) expression is increased in PCa and is an actionable...
4.
Moon D, Hauck J, Jiang X, Quang H, Xu L, Zhang F, et al.
Prostate
. 2023 Dec;
84(4):349-357.
PMID: 38084059
Background: Prostate cancer (PCa) continues to be one of the leading causes of cancer deaths in men. While androgen deprivation therapy is initially effective, castration-resistant PCa (CRPC) often recurs and...
5.
Butler W, Xu L, Zhou Y, Cheng Q, Hauck J, He Y, et al.
J Pathol
. 2023 Feb;
260(1):43-55.
PMID: 36752189
Neuroendocrine (NE) cells comprise ~1% of epithelial cells in benign prostate and prostatic adenocarcinoma (PCa). However, they become enriched in hormonally treated and castration-resistant PCa (CRPC). In addition, close to...
6.
Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson N, et al.
Nat Cancer
. 2022 Oct;
3(10):1271.
PMID: 36241729
No abstract available.
7.
Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson N, et al.
Nat Cancer
. 2022 Sep;
3(9):1071-1087.
PMID: 36065066
Emerging evidence indicates that various cancers can gain resistance to targeted therapies by acquiring lineage plasticity. Although various genomic and transcriptomic aberrations correlate with lineage plasticity, the molecular mechanisms enabling...
8.
Xu H, Liu Z, Gao D, Li P, Shen Y, Sun Y, et al.
Mol Metab
. 2022 Feb;
59:101466.
PMID: 35219875
Cell lineage reprogramming is the main approach for cancer cells to acquire drug resistance and escape targeted therapy. The use of potent targeted therapies in cancers has led to the...
9.
Xu L, Zhao B, Butler W, Xu H, Song N, Chen X, et al.
Oncogene
. 2022 Jan;
41(8):1140-1154.
PMID: 35046532
Advanced and aggressive prostate cancer (PCa) depends on glutamine for survival and proliferation. We have previously shown that inhibition of glutaminase 1, which catalyzes the rate-limiting step of glutamine catabolism,...
10.
Tao J, Liu G, Liang C, Hao Z, Yang C, Shi H, et al.
J Laparoendosc Adv Surg Tech A
. 2021 Dec;
32(6):646-652.
PMID: 34936488
The surgical treatment of horseshoe kidney (HSK) remains a huge challenge because of the complex anatomy and abnormal blood vessel distribution. Therefore, this study aimed to evaluate the surgical technique...